Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ: IMVT ) with a Buy and raises the price target from $57 to $61.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.